Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 193

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 193
---
. Mr. Jeff Dykan. is the general partner of the foregoing entities, and, as such, holds share voting and dispositive power over   
 the shares held by the foregoing entities. The principal business address of SCP Vitalife Partners II L.P., is Messrs. Churchill     
 and Weisman, 5 Great Valley Parkway, Suite 210, Malvern, Pennsylvania 19355. The principal business address of SCP Vitalife Partners 
 (Israel) II L.P. is 15 Hatidhar, P.O. Box 2138, Raanana, Tel Aviv 4366517, Israel.                                                   |
| (8) | Consists of options to purchase up to 37,500 Ordinary Shares.                                                                        |

<div align='center'>113

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

The following is a description
of the material terms of those transactions with related parties to which we are party.

Convertible Loans

In September of 2021, we entered
into several convertible loan agreements, or the 2021 CLAs, pursuant to which we obtained a convertible loan in the aggregate amount of
$835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the Company of the same class of the
conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 88,385 Ordinary Shares and the warrants granted
thereunder expired in full in December 2023.

Between August 2020 and February
2021, we entered into the 2020 CLAs, pursuant to which we obtained a convertible loan in the aggregate amount of $900,000. The 2020 CLAs
have been extended until August 31, 2025. In October 2024, or the October 2024 Addendum, we proposed to the lenders under the 2020 CLAs
to increase principal amount under their respective portion of the 2020 CLA, up to an additional aggregate amount of $450,000, so that
the 2020 CLAs shall bear interest at 8% per annum until maturity commencing as of July 1, 2024 with respect to non-participating lenders
and March 31, 2025 with respect to participating lenders. In addition, pursuant to the October 2024 Addendum, we agreed to pay the participating
lenders at maturity an additional aggregate amount of 340,000